There are opportunities to investigate molecular mechanisms in myeloid blood cancers including epigenetic alterations, DNA repair deficiency, altered signal pathways to identify therapeutic targets for novel agents or repurposed drugs using drug screens and/or NGS technologies to improve patient outcomes.
Research activity per year
If you made any changes in Pure these will be visible here soon.
Dive into the research topics where Ken Mills is active. These topic labels come from the works of this person. Together they form a unique fingerprint.